PHARMACOLOGICAL TREATMENT OF PTSD WITH PSYCHEDELICS: A FUTURE OUTLOOK
Abstract
Globally, approximately 3.9% of the population is estimated to experience Post Traumatic Stress Disorder during their lifetime. PTSD is characterized as a complex mental health condition that develops following exposure to traumatic events, manifesting through intrusive thoughts, hyperarousal, and avoidance behaviors. Despite psychotherapy and conventional pharmacotherapy being the standard primary treatments, a significant number of individuals with PTSD continue to suffer from chronic symptoms and substantial psychiatric and medical comorbidities, underscoring a critical need for innovative therapeutic interventions.
A broad consensus in the literature indicates that existing PTSD treatments offer only marginal effectiveness for a considerable proportion of affected individuals. To address this, the present narrative review endeavors to synthesize the available knowledge regarding novel treatments for PTSD, specifically focusing on psychedelic drugs, acknowledging the current limitations in high-quality empirical literature on the subject.
The primary objective of this study is to conduct a narrative review on the efficacy of psychedelic therapy in managing PTSD. This involves examining current research and evaluating the benefits and drawbacks associated with various psychedelic interventions. The central clinical question explored is: For patients diagnosed with PTSD, what are the current and emerging psychedelic-based pharmacological treatments, and what is their prospective role in future clinical integration?
It is anticipated that this study will provide valuable insights to both practitioners and patients regarding the potential utility of psychedelic compounds within the therapeutic landscape of PTSD.
References
Abdallah, C. G., Roache, J. D., Gueorguieva, R., Averill, L. A., Young‐McCaughan, S., Shiroma, P., Purohit, P., Brundige, A., Murff, W., Ahn, K.-H., Sherif, M., Baltutis, E. J., Ranganathan, M., D’Souza, D. C., Martini, B., Southwick, S. M., Petrakis, I. L., Burson, R. R., Guthmiller, K. B., … Krystal, J. H. (2022). Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology, 47(8), 1574. https://doi.org/10.1038/s41386-022-01266-9
Ali, S., Tian, X., Cunningham, K. A., & Zhou, J. (2025). Old Dog, New Tricks: Ibogaine and Its Analogs as Potential Neurotherapeutics. Journal of Medicinal Chemistry, 68(18), 18744. https://doi.org/10.1021/acs.jmedchem.5c02510
Almeida, T. M., Martins, M., Cordeiro, Q., & Uchida, R. R. (2024). EFFECTIVENESS OF KETAMINE FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER – A SYSTEMATIC REVIEW AND META-ANALYSIS. https://doi.org/10.36131/cnfioritieditore20240102
Andualem, F., Melkam, M., Takelle, G. M., Nakie, G., Tinsae, T., Fentahun, S., Rtbey, G., Begashaw, T. D., Seid, J., Tegegn, L. F., Gedef, G. M., Bitew, D. A., & Godana, T. N. (2024). Prevalence of posttraumatic stress disorder and associated factors among displaced people in Africa: a systematic review and meta-analysis [Review of Prevalence of posttraumatic stress disorder and associated factors among displaced people in Africa: a systematic review and meta-analysis]. Frontiers in Psychiatry, 15, 1336665. Frontiers Media. https://doi.org/10.3389/fpsyt.2024.1336665
Askariyan, K., Joghataei, M. T., Dehghan, S., Nohesara, S., Rihipour, L., Mohammadi, M. H., & Ahmadirad, N. (2025). An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions [Review of An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions]. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 111461. Elsevier BV. https://doi.org/10.1016/j.pnpbp.2025.111461
Azevedo, M., Martinho, R., Oliveira, A., Correia‐de‐Sá, P., & Moreira-Rodrigues, M. (2024). Molecular pathways underlying sympathetic autonomic overshooting leading to fear and traumatic memories: looking for alternative therapeutic options for post-traumatic stress disorder [Review of Molecular pathways underlying sympathetic autonomic overshooting leading to fear and traumatic memories: looking for alternative therapeutic options for post-traumatic stress disorder]. Frontiers in Molecular Neuroscience, 16. Frontiers Media. https://doi.org/10.3389/fnmol.2023.1332348
Beaglehole, B., Glue, P., Neehoff, S., Shadli, S., McNaughton, N., Kimber, B., Muirhead, C., De Bie, A., Day-Brown, R., & Hughes-Medlicott, N. J. (2025). Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study. BJPsych Open, 11(6). https://doi.org/10.1192/bjo.2025.10854
Bell, R. F., & Kalso, E. (2018). Ketamine for pain management. PAIN Reports, 3(5). https://doi.org/10.1097/pr9.0000000000000674
Benzenhöfer, U., & Passie, T. (2010). Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin. Addiction, 105(8), 1355. https://doi.org/10.1111/j.1360-0443.2010.02948.x
Bird, C. I. V., Modlin, N. L., & Rucker, J. J. H. (2021). Psilocybin and MDMA for the treatment of trauma-related psychopathology. International Review of Psychiatry, 33(3), 229. https://doi.org/10.1080/09540261.2021.1919062
Bryant, R. A., Nickerson, A., Morina, N., & Liddell, B. J. (2023). Posttraumatic Stress Disorder in Refugees [Review of Posttraumatic Stress Disorder in Refugees]. Annual Review of Clinical Psychology, 19(1), 413. Annual Reviews. https://doi.org/10.1146/annurev-clinpsy-080921-080359
Carlson, E. B., Shieh, L., Barlow, M., Palmieri, P. A., Yen, F., Mellman, T. A., Williams, M., Williams, M. Y., Chandran, M., & Spain, D. A. (2023). Mental health symptoms are comparable in patients hospitalized with acute illness and patients hospitalized with injury. PLoS ONE, 18(9). https://doi.org/10.1371/journal.pone.0286563
Charney, D. S. (1993). Psychobiologic Mechanisms of Posttraumatic Stress Disorder [Review of Psychobiologic Mechanisms of Posttraumatic Stress Disorder]. Archives of General Psychiatry, 50(4), 294. American Medical Association. https://doi.org/10.1001/archpsyc.1993.01820160064008
Cherian, K., Shinozuka, K., Tabaac, B. J., Arenas, A., Beutler, B. D., Evans, V. D., Fasano, C., & Muir, O. S. (2024). Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine. American Journal of Therapeutics, 31(2). https://doi.org/10.1097/MJT.0000000000001723
Chiu, H. T. S., Chan, A. H. T., & Meiser‐Stedman, R. (2023). Relationship Between Anxiety Sensitivity and Post-Traumatic Stress Symptoms in Trauma-Exposed Children and Adolescents: A Meta-Analysis. Cognitive Therapy and Research, 48(3), 371. https://doi.org/10.1007/s10608-023-10427-z
Choi, C. Q., Johnson, D. E., Chen‐Li, D., & Rosenblat, J. D. (2024). Mechanisms of psilocybin on the treatment of posttraumatic stress disorder [Review of Mechanisms of psilocybin on the treatment of posttraumatic stress disorder]. Journal of Psychopharmacology. SAGE Publishing. https://doi.org/10.1177/02698811241286771
Colcott, J., Guerin, A. A., Carter, O., Meikle, S., & Bedi, G. (2024). Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis. Neuropsychopharmacology, 49(8), 1208. https://doi.org/10.1038/s41386-024-01865-8
Court, R. C. V., Wiseman, M. S., Meyer, K., Ballhorn, D. J., Amses, K. R., Slot, J. C., Dentinger, B. T. M., Garibay‐Orijel, R., & Uehling, J. K. (2022). Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development [Review of Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development]. Fungal Biology, 126(4), 308. Elsevier BV. https://doi.org/10.1016/j.funbio.2022.01.003
Daniel, J., & Haberman, M. (2017). Clinical potential of psilocybin as a treatment for mental health conditions. Mental Health Clinician, 7(1), 24. https://doi.org/10.9740/mhc.2017.01.024
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020). Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress, 4. https://doi.org/10.1177/2470547020939564
Davis, L. L., Schein, J., Cloutier, M., Gagnon‐Sanschagrin, P., Maitland, J., Urganus, A., Guérin, A., Lefèbvre, P., & Houle, C. R. (2022). The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective. The Journal of Clinical Psychiatry, 83(3). https://doi.org/10.4088/jcp.21m14116
Day, J., & Agrawal, D. K. (2025). High and Low Dose Ketamine in Post-Traumatic Stress Disorder. https://doi.org/10.26502/acc.078
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2022). Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy [Review of Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy]. CNS Spectrums, 28(4), 416. Cambridge University Press. https://doi.org/10.1017/s1092852922000888
Dourron, H. M., Nichols, C. D., Simonsson, O., Bradley, M., Carhart‐Harris, R., & Hendricks, P. S. (2023). 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk? [Review of 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?]. Psychopharmacology, 242(7), 1457. Springer Science+Business Media. https://doi.org/10.1007/s00213-023-06517-1
Du, J., Diao, H., Zhou, X., Zhang, C., Chen, Y., Gao, Y., & Wang, Y. (2022). Post-traumatic stress disorder: a psychiatric disorder requiring urgent attention [Review of Post-traumatic stress disorder: a psychiatric disorder requiring urgent attention]. Medical Review, 2(3), 219. De Gruyter. https://doi.org/10.1515/mr-2022-0012
Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2021). A narrative synthesis of research with 5-MeO-DMT [Review of A narrative synthesis of research with 5-MeO-DMT]. Journal of Psychopharmacology, 36(3), 273. SAGE Publishing. https://doi.org/10.1177/02698811211050543
Ermakova, A. O., Dunbar, F., Seynaeve, M., & Millière, R. (2025). Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults. Scientific Reports, 15(1), 38874. https://doi.org/10.1038/s41598-025-22620-z
Feduccia, A. A., Holland, J., & Mithoefer, M. C. (2017). Progress and promise for the MDMA drug development program. Psychopharmacology, 235(2), 561. https://doi.org/10.1007/s00213-017-4779-2
Ferretti, F., Pozza, A., Bossini, L., Desantis, S., Olivola, M., Matto, L. D., Gualtieri, G., Gusinu, R., Bezzini, D., Fagiolini, A., & Coluccia, A. (2019). Post-traumatic stress disorder in Italy: a comprehensive evaluation of all the ICD comorbidities and gender-related differences. BMC Research Notes, 12(1). https://doi.org/10.1186/s13104-019-4792-0
First, M. B., Clarke, D. E., Yousif, L. H., Eng, A. M., Gogtay, N., & Appelbaum, P. S. (2022). DSM-5-TR: Rationale, Process, and Overview of Changes. Psychiatric Services, 74(8), 869. https://doi.org/10.1176/appi.ps.20220334
Freudenmann, R. W., Öxler, F., & Bernschneider‐Reif, S. (2006). The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*. Addiction, 101(9), 1241. https://doi.org/10.1111/j.1360-0443.2006.01511.x
Fuller, R. G., Kikla, E. M., Fawcett, A. P. W., Hesling, J. D., Keenan, S., Flarity, K., Patzkowski, M. S., April, M. D., Bebarta, V. S., & Schauer, S. G. (2024). Low-dose ketamine for acute pain: A narrative review [Review of Low-dose ketamine for acute pain: A narrative review]. The American Journal of Emergency Medicine, 86, 41. Elsevier BV. https://doi.org/10.1016/j.ajem.2024.09.033
Fung, H. W., Leousi, A., Chau, A. K. C., Sit, K. Y., Lam, C. C., Li, C. M., Huang, C. H. O., Cheung, C. T. Y., Lam, S. K. K., Wang, E. K. S., & Ho, G. W. K. (2025). Prevalence of ICD-11 post-traumatic stress disorder (PTSD) and complex PTSD in the general populations: A systematic review and meta-analysis [Review of Prevalence of ICD-11 post-traumatic stress disorder (PTSD) and complex PTSD in the general populations: A systematic review and meta-analysis]. Asian Journal of Psychiatry, 110, 104610. Elsevier BV. https://doi.org/10.1016/j.ajp.2025.104610
Gibuła‐Tarłowska, E., Wiszniewska, A., Turyk, M., Szymczyk, P., Kotlińska, J. H., & Kędzierska, E. (2025). Ketamine—From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks [Review of Ketamine—From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks]. Molecules, 30(13), 2824. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/molecules30132824
Glatfelter, G. C., Pottie, E., Partilla, J. S., Sherwood, A. M., Kaylo, K. W., Pham, D. N. K., Naeem, M., Sammeta, V. R., DeBoer, S., Golen, J. A., Hulley, E. B., Stove, C. P., Chadeayne, A. R., Manke, D. R., & Baumann, M. H. (2022). Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice. ACS Pharmacology & Translational Science, 5(11), 1181. https://doi.org/10.1021/acsptsci.2c00177
Golitaleb, M., Mazaheri, E., Bonyadi, M., & Sahebi, A. (2022). Prevalence of Post-traumatic Stress Disorder After Flood: A Systematic Review and Meta-Analysis [Review of Prevalence of Post-traumatic Stress Disorder After Flood: A Systematic Review and Meta-Analysis]. Frontiers in Psychiatry, 13, 890671. Frontiers Media. https://doi.org/10.3389/fpsyt.2022.890671
Greer, G., & Tolbert, R. (1986). Subjective Reports of the Effects of MDMA in a Clinical Setting. Journal of Psychoactive Drugs, 18(4), 319. https://doi.org/10.1080/02791072.1986.10472364
Greer, G., & Tolbert, R. (1990). The Therapeutic Use of MDMA. In Topics in the neurosciences (p. 21). Springer Nature. https://doi.org/10.1007/978-1-4613-1485-1_2
Greer, G., & Tolbert, R. (1998). A Method of Conducting Therapeutic Sessions with MDMA. Journal of Psychoactive Drugs, 30(4), 371. https://doi.org/10.1080/02791072.1998.10399713
Handiso, D. W., Belsti, Y., Boyle, J., Paul, E., Shawyer, F., & Enticott, J. (2023). A Systematic Review and Meta-Analysis of Longitudinal Studies on Posttraumatic Stress Disorders in Refugees and Asylum Seekers [Review of A Systematic Review and Meta-Analysis of Longitudinal Studies on Posttraumatic Stress Disorders in Refugees and Asylum Seekers]. International Journal of Mental Health and Addiction. Springer Science+Business Media. https://doi.org/10.1007/s11469-023-01172-1
Harnett, N. G., Goodman, A. M., & Knight, D. C. (2020). PTSD-related neuroimaging abnormalities in brain function, structure, and biochemistry [Review of PTSD-related neuroimaging abnormalities in brain function, structure, and biochemistry]. Experimental Neurology, 330, 113331. Elsevier BV. https://doi.org/10.1016/j.expneurol.2020.113331
Hayes, J. P., VanElzakker, M. B., & Shin, L. M. (2012). Emotion and cognition interactions in PTSD: a review of neurocognitive and neuroimaging studies [Review of Emotion and cognition interactions in PTSD: a review of neurocognitive and neuroimaging studies]. Frontiers in Integrative Neuroscience, 6, 89. Frontiers Media. https://doi.org/10.3389/fnint.2012.00089
Hinojosa, C. A., George, G., & Ben‐Zion, Z. (2024). Neuroimaging of posttraumatic stress disorder in adults and youth: progress over the last decade on three leading questions of the field [Review of Neuroimaging of posttraumatic stress disorder in adults and youth: progress over the last decade on three leading questions of the field]. Molecular Psychiatry, 29(10), 3223. Springer Nature. https://doi.org/10.1038/s41380-024-02558-w
Hirota, K., & Lambert, D. G. (2022). Ketamine; history and role in anesthetic pharmacology [Review of Ketamine; history and role in anesthetic pharmacology]. Neuropharmacology, 216, 109171. Elsevier BV. https://doi.org/10.1016/j.neuropharm.2022.109171
Hofmann, A., Frey, A., Ott, H., Petrzilka, Th., & Troxler, F. (1958). Konstitutionsaufklärung und Synthese von Psilocybin. Cellular and Molecular Life Sciences, 14(11), 397. https://doi.org/10.1007/bf02160424
Holas, P., & Kamińska, J. (2023). Mindfulness meditation and psychedelics: potential synergies and commonalities [Review of Mindfulness meditation and psychedelics: potential synergies and commonalities]. Pharmacological Reports, 75(6), 1398. Elsevier BV. https://doi.org/10.1007/s43440-023-00551-8
Iqbal, J., Huang, G.-D., Xue, Y.-X., Yang, M., & Jia, X. (2023). The neural circuits and molecular mechanisms underlying fear dysregulation in posttraumatic stress disorder. Frontiers in Neuroscience, 17, 1281401. https://doi.org/10.3389/fnins.2023.1281401
Irizarry, R., Winczura, A., Dimassi, O., Dhillon, N., Minhas, A., & Larice, J. (2022). Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.31796
IsHak, W. W., García, P., Pearl, R., Dang, J., William, C., Totlani, J., & Danovitch, I. (2023). The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials. [Review of The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.]. PubMed, 20, 39. National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov/37387703
Jefferson, S. J., Gregg, I., Dibbs, M., Liao, C., Wu, H., Davoudian, P. A., Woodburn, S. C., Wehrle, P. H., Sprouse, J., Sherwood, A. M., Kaye, A. P., Pittenger, C., & Kwan, A. C. (2023). 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology, 48(9), 1257. https://doi.org/10.1038/s41386-023-01572-w
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2023). Ketamine in neuropsychiatric disorders: an update [Review of Ketamine in neuropsychiatric disorders: an update]. Neuropsychopharmacology, 49(1), 23. Springer Nature. https://doi.org/10.1038/s41386-023-01632-1
Jones, K., Boschen, M. J., Devilly, G. J., Vogler, J., Flowers, H., Winkleman, C., & Wullschleger, M. (2024). Risk and protective factors that predict posttraumatic stress disorder after traumatic injury: A systematic review [Review of Risk and protective factors that predict posttraumatic stress disorder after traumatic injury: A systematic review]. Health Sciences Review, 10, 100147. Elsevier BV. https://doi.org/10.1016/j.hsr.2023.100147
Jowf, G. I. A., Ahmed, Z. T., An, N., Reijnders, R. A., Ambrosino, E., Rutten, B. P. F., Nijs, L. de, & Eijssen, L. (2022). A Public Health Perspective of Post-Traumatic Stress Disorder [Review of A Public Health Perspective of Post-Traumatic Stress Disorder]. International Journal of Environmental Research and Public Health, 19(11), 6474. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ijerph19116474
Kaminski, D., & Reinert, J. P. (2023). The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review [Review of The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review]. Annals of Pharmacotherapy, 58(8), 811. SAGE Publishing. https://doi.org/10.1177/10600280231205645
Kargbo, R. B., Sherwood, A. M., Walker, A. J., Cozzi, N. V., Dagger, R. E., Sable, J., O’Hern, K., Kaylo, K. W., Patterson, T., Tarpley, G., & Meisenheimer, P. (2020). Direct Phosphorylation of Psilocin Enables Optimized cGMP Kilogram-Scale Manufacture of Psilocybin. ACS Omega, 5(27), 16959. https://doi.org/10.1021/acsomega.0c02387
Khsim, I. E. F., Rodríguez, M. M., Riquelme‐Gallego, B., Caparrós-González, R. A., & Amezcua‐Prieto, C. (2022). Risk Factors for Post-Traumatic Stress Disorder after Childbirth: A Systematic Review [Review of Risk Factors for Post-Traumatic Stress Disorder after Childbirth: A Systematic Review]. Diagnostics, 12(11), 2598. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/diagnostics12112598
Koenen, K. C., Ratanatharathorn, A., Ng, L. C., McLaughlin, K. A., Bromet, E. J., Stein, D. J., Karam, E. G., Ruscio, A. M., Benjet, C., Scott, K. M., Atwoli, L., Petukhova, M., Lim, C., Aguilar‐Gaxiola, S., Malik, A., Alonso, J., Bunting, B., Ciutan, M., Girolamo, G. de, … Kessler, R. C. (2017). Posttraumatic stress disorder in the World Mental Health Surveys. Psychological Medicine, 47(13), 2260. https://doi.org/10.1017/s0033291717000708
Krabbe, A., Sikka, P., & Jylkkä, J. (2024). Acceptance as a possible link between past psychedelic experiences and psychological flexibility. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-75595-8
Krediet, E., Bostoen, T., Breeksema, J., Van Schagen, A., Passie, T., & Vermetten, E. (2020). Reviewing the Potential of Psychedelics for the Treatment of PTSD. International Journal of Neuropsychopharmacology, 23(6), 385. https://doi.org/10.1093/ijnp/pyaa018
Kwaśny, A., Wilkowska, A., & Cubała, W. J. (2024). Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials [Review of Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials]. Frontiers in Psychiatry, 15, 1477996. Frontiers Media. https://doi.org/10.3389/fpsyt.2024.1477996
Lawrence, D. W., Carhart‐Harris, R., Griffiths, R. R., & Timmermann, C. (2022). Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-11999-8
Lechner‐Meichsner, F., Comteße, H., & Olk, M. (2024). Prevalence, comorbidities, and factors associated with prolonged grief disorder, posttraumatic stress disorder and complex posttraumatic stress disorder in refugees: a systematic review [Review of Prevalence, comorbidities, and factors associated with prolonged grief disorder, posttraumatic stress disorder and complex posttraumatic stress disorder in refugees: a systematic review]. Conflict and Health, 18(1), 32. BioMed Central. https://doi.org/10.1186/s13031-024-00586-5
Lewis, B. R., & Byrne, K. (2023). A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder. Focus, 21(3), 247. https://doi.org/10.1176/appi.focus.20220088
Li, L., Shen, X., Zeng, G., Huang, H., Chen, Z., Yang, J., Wang, X., Jiang, M., Yang, S., Zhang, Q., & Li, H. (2023). Sexual violence against women remains problematic and highly prevalent around the world [Review of Sexual violence against women remains problematic and highly prevalent around the world]. BMC Women s Health, 23(1), 196. BioMed Central. https://doi.org/10.1186/s12905-023-02338-8
Lunkenheimer, F., Garatva, P., Steubl, L., & Baumeister, H. (2023). Prevalence and incidence of post-traumatic stress disorder and symptoms in people with chronic somatic diseases: A systematic review and meta-analysis [Review of Prevalence and incidence of post-traumatic stress disorder and symptoms in people with chronic somatic diseases: A systematic review and meta-analysis]. Frontiers in Psychiatry, 14, 1107144. Frontiers Media. https://doi.org/10.3389/fpsyt.2023.1107144
Mandagere, K., Stoy, S., Hammerle, N., Zapata, I., & Brooks, B. A. (2025). Systematic review and meta-analysis of post-traumatic stress disorder as a risk factor for multiple autoimmune diseases [Review of Systematic review and meta-analysis of post-traumatic stress disorder as a risk factor for multiple autoimmune diseases]. Frontiers in Psychiatry, 16, 1523994. Frontiers Media. https://doi.org/10.3389/fpsyt.2025.1523994
McGowan, N. M., Rucker, J. J., Yehuda, R., Agrawal, M., Modlin, N. L., Simmons, H., Tofil-Kaluza, A., Das, S., & Goodwin, G. M. (2025). Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. https://doi.org/10.1177/02698811251362390
Meyer, J. (2013). 3,4-methylenedioxymethamphetamine (MDMA): current perspectives [Review of 3,4-methylenedioxymethamphetamine (MDMA): current perspectives]. Substance Abuse and Rehabilitation, 83. Dove Medical Press. https://doi.org/10.2147/sar.s37258
Miller, C. E., & Zoladz, P. R. (2025). Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder. The Journal of Pharmacology and Experimental Therapeutics, 392(1), 100026. https://doi.org/10.1124/jpet.124.002237
Millón, M. B. B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D. E., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L., Garcés, M. A., Díez, P., Albarracín, S. G., & Bruno, M. A. (2025). Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study. Neuropsychopharmacology, 50(11), 1715. https://doi.org/10.1038/s41386-025-02167-3
Mion, G., & Villevieille, T. (2013). Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings). CNS Neuroscience & Therapeutics, 19(6), 370. https://doi.org/10.1111/cns.12099
Mitchell, J., Bogenschutz, M. P., Lilienstein, A., Harrison, C., Kleiman, S. E., Parker-Guilbert, K., G., M. O., Garas, W., Paleos, C., Gorman, I., Nicholas, C. R., Mithoefer, M. C., Carlin, S., Poulter, B., Mithoefer, A. T., Quevedo, S., Wells, G. B., Klaire, S., Kolk, B. van der, … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025. https://doi.org/10.1038/s41591-021-01336-3
Mitchell, J., G., M. O., Kolk, B. van der, Shannon, S., Bogenschutz, M. P., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M. C., Kleiman, S. E., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., Boer, A. de, Doblin, R., Yazar‐Klosinski, B., … Emerson, A. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473. https://doi.org/10.1038/s41591-023-02565-4
Moder, J., Sadowska, A., Piasecka, A., Sobiński, A., Miśkiewicz, J., Dudek, A., Pietrusińska, P., Śliwa-Tytko, P., Dziewierz, A., & Kwaśniewska, P. (2025). Post-Traumatic Stress Disorder and its Somatic Comorbidities: A Review [Review of Post-Traumatic Stress Disorder and its Somatic Comorbidities: A Review]. Journal of Education Health and Sport, 80, 59387. Kazimierz Wielki University in Bydgoszcz. https://doi.org/10.12775/jehs.2025.80.59387
Mohamed, A., Touheed, S., Ahmed, M., Hor, M., & Fatima, S. (2022). The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier? Cureus. https://doi.org/10.7759/cureus.30919
Nguyen, K., Mukona, L. T., Nalbandyan, L., Yar, N., Fleur, G. St., Mukona, L., Hernandez, E. W., & Lamberty, N. (2022). Peripartum Complications as Risk Factors for Postpartum Psychosis: A Systemic Review [Review of Peripartum Complications as Risk Factors for Postpartum Psychosis: A Systemic Review]. Cureus. Cureus, Inc. https://doi.org/10.7759/cureus.29224
Nievergelt, C. M., Maihofer, A. X., Atkinson, E. G., Chen, C., Choi, K. W., Coleman, J. R. I., Daskalakis, N. P., Duncan, L. E., Polimanti, R., Aaronson, C. J., Amstadter, A. B., Andersen, S. B., Andreassen, O. A., Arbisi, P. A., Ashley‐Koch, A. E., Austin, S. B., Avdibegović, E., Babić, D., Bacanu, S., … Johnson, J. (2023). Discovery of 95 PTSD loci provides insight into genetic architecture and neurobiology of trauma and stress-related disorders. medRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2023.08.31.23294915
Nogueira, M., Golbert, D. F., Menezes, R., Almeida, R. N. de, Coelho, N., Siroký, A., Lima, T., Maia, H., Leão, K. E., & Leão, R. N. (2023). Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice. Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-3787978/v1
Nowak, A. C., Nutsch, N., Brake, T.-M., Gehrlein, L.-M., & Razum, O. (2023). Associations between postmigration living situation and symptoms of common mental disorders in adult refugees in Europe: updating systematic review from 2015 onwards [Review of Associations between postmigration living situation and symptoms of common mental disorders in adult refugees in Europe: updating systematic review from 2015 onwards]. BMC Public Health, 23(1), 1289. BioMed Central. https://doi.org/10.1186/s12889-023-15931-1
Omidian, H., & Omidian, A. (2025). The Emergence of Psilocybin in Psychiatry and Neuroscience [Review of The Emergence of Psilocybin in Psychiatry and Neuroscience]. Pharmaceuticals, 18(4), 555. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ph18040555
Passie, T. (2018). The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985). Drug Science Policy and Law, 4. https://doi.org/10.1177/2050324518767442
Patanè, M., Ghane, S., Karyotaki, E., Cuijpers, P., Schoonmade, L., Tarsitani, L., & Sijbrandij, M. (2022). Prevalence of mental disorders in refugees and asylum seekers: a systematic review and meta-analysis [Review of Prevalence of mental disorders in refugees and asylum seekers: a systematic review and meta-analysis]. Cambridge Prisms Global Mental Health, 9, 250. Cambridge University Press. https://doi.org/10.1017/gmh.2022.29
Polo-Castellano, C., Álvarez, J. A., Palma, M., Barbero, G. F., Ayuso, J., & Ferreiro‐González, M. (2022). Optimization through a Box–Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (Psylocibe cubensis). Journal of Fungi, 8(6), 598. https://doi.org/10.3390/jof8060598
Qassem, T., Aly-ElGabry, D., Alzarouni, A., Aziz, K. A., & Arnone, D. (2020). Psychiatric Co-Morbidities in Post-Traumatic Stress Disorder: Detailed Findings from the Adult Psychiatric Morbidity Survey in the English Population. Psychiatric Quarterly, 92(1), 321. https://doi.org/10.1007/s11126-020-09797-4
Ragnhildstveit, A., Khan, R., Seli, P., Bass, L. C., August, R. J., Kaiyo, M., Barr, N., Jackson, L. K., Gaffrey, M. S., Barsuglia, J. P., & Averill, L. A. (2023). 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study. Frontiers in Psychiatry, 14, 1271152. https://doi.org/10.3389/fpsyt.2023.1271152
Reckweg, J. T., Mason, N. L., Leeuwen, C. van, Toennes, S. W., Terwey, T. H., & Ramaekers, J. G. (2021). A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.760671
Reckweg, J. T., Uthaug, M. V., Szabó, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) [Review of The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)]. Journal of Neurochemistry, 162(1), 128. Wiley. https://doi.org/10.1111/jnc.15587
Reddy, A., Patel, S., Barik, A. K., Thappa, P., Jangra, K., Kaur, K., Chauhan, R., & Luthra, A. (2024). The Role of Ketamine in Treatment-resistant Depression: A Narrative Review [Review of The Role of Ketamine in Treatment-resistant Depression: A Narrative Review]. Journal of Exploratory Research in Pharmacology, 0. https://doi.org/10.14218/jerp.2024.00003
Ressler, K. J., Berretta, S., Bolshakov, V. Y., Rosso, I. M., Meloni, E. G., Rauch, S. L., & Carlezon, W. A. (2022). Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits [Review of Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits]. Nature Reviews Neurology, 18(5), 273. Nature Portfolio. https://doi.org/10.1038/s41582-022-00635-8
Rheingold, A. A., Williams, J. L., & Bottomley, J. S. (2024). Prevalence and Co-Occurrence of Psychiatric Conditions Among Bereaved Adults. JAMA Network Open, 7(6). https://doi.org/10.1001/jamanetworkopen.2024.15325
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2024). Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review [Review of Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review]. Psychiatry Research, 335, 115880. Elsevier BV. https://doi.org/10.1016/j.psychres.2024.115880
Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022). Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review [Review of Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review]. Psychopharmacology, 239(6), 1945. Springer Science+Business Media. https://doi.org/10.1007/s00213-022-06083-y
Sbisa, A., Graham, K., Lawrence‐Wood, E., McFarlane, A. C., & Toben, C. (2024). PTSD biomarkers: Neuroendocrine signaling to epigenetic variants [Review of PTSD biomarkers: Neuroendocrine signaling to epigenetic variants]. Advances in Clinical Chemistry. Elsevier BV. https://doi.org/10.1016/bs.acc.2024.06.004
Schincariol, A., Orrù, G., Otgaar, H., Sartori, G., & Scarpazza, C. (2024). Posttraumatic stress disorder (PTSD) prevalence: an umbrella review [Review of Posttraumatic stress disorder (PTSD) prevalence: an umbrella review]. Psychological Medicine, 1. Cambridge University Press. https://doi.org/10.1017/s0033291724002319
Schuitmaker, N. (2023). Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies [Review of Psilocybin-Assisted Therapy: A scoping review of participants’ and facilitators’ experiences in qualitative studies]. Research Society and Development, 12(9). Grupo de Pesquisa Metodologias em Ensino e Aprendizagem em Ciências. https://doi.org/10.33448/rsd-v12i9.43308
Seah, C., Sidamon‐Eristoff, A. E., Huckins, L. M., & Brennand, K. (2025). Implications of gene × environment interactions in post-traumatic stress disorder risk and treatment [Review of Implications of gene × environment interactions in post-traumatic stress disorder risk and treatment]. Journal of Clinical Investigation, 135(5). American Society for Clinical Investigation. https://doi.org/10.1172/jci185102
Sep, M. S. C., Geuze, E., & Joëls, M. (2021). Impaired learning, memory, and extinction in posttraumatic stress disorder: translational meta-analysis of clinical and preclinical studies. medRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2021.07.19.21260790
Sicignano, D. J., Kurschner, R., Weisman, N., Sedensky, A., Hernandez, A. V., & White, C. M. (2024). The Impact of Ketamine for Treatment of Post-Traumatic Stress Disorder: A Systematic Review With Meta-Analyses. Annals of Pharmacotherapy, 58(7), 669. https://doi.org/10.1177/10600280231199666
Siddaway, A. P. (2024). Assessment and diagnosis of post-traumatic stress disorders (PTSDs) for medico-legal and other clinical purposes: DSM-5-TR PTSD, ICD-11 PTSD and ICD-11 complex PTSD. BJPsych Advances, 30(6), 383. https://doi.org/10.1192/bja.2024.27
Siddaway, A. P. (2025). Flashbacks uniquely characterise post-traumatic stress disorder: distinguishing flashbacks from other psychological processes and phenomena. BJPsych Advances, 1. https://doi.org/10.1192/bja.2025.3
Sippel, L. M., Hamblen, J. L., Kelmendi, B., Alpert, J. E., Carpenter, L. L., Grzenda, A., Kraguljac, N., McDonald, W. M., Rodriguez, C. I., Widge, A. S., Nemeroff, C. B., Schnurr, P. P., & Holtzheimer, P. E. (2024). Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence. American Journal of Psychiatry, 181(12), 1045. https://doi.org/10.1176/appi.ajp.20230950
Smith, K. W., Sicignano, D. J., Hernández, A. V., & White, C. M. (2021). MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis [Review of MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis]. The Journal of Clinical Pharmacology, 62(4), 463. Wiley. https://doi.org/10.1002/jcph.1995
Sottile, R. J., & Vida, T. (2022). A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy [Review of A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy]. Frontiers in Psychiatry, 13. Frontiers Media. https://doi.org/10.3389/fpsyt.2022.991753
Stanicic, F., Zah, V., Grbic, D., Angelo, D. de, & Bibeau, W. S. (2024). Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients. Journal of Comparative Effectiveness Research, 13(12). https://doi.org/10.57264/cer-2024-0058
Stavely, C. D. (2025). EXPLORING IBOGAINE/5-MEO-DMT AS TREATMENT FOR THE RELIEF OF PTSD SYMPTOMS IN VETERANS. https://www.centreforevidence.org/article/20250608-exploring-ibogaine-5-meo-dmt-as-treatment-for-the-relief-of-ptsd-symptoms-in-veterans
Stocker, K., & Liechti, M. E. (2024). Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile “the great entactogen—empathogen debate” [Review of Methylenedioxymethamphetamine is a connectogen with empathogenic, entactogenic, and still further connective properties: It is time to reconcile “the great entactogen—empathogen debate”]. Journal of Psychopharmacology, 38(8), 685. SAGE Publishing. https://doi.org/10.1177/02698811241265352
Straumann, I., Holze, F., Becker, A., Ley, L., Halter, N., & Liechti, M. E. (2024). Safety pharmacology of acute psilocybin administration in healthy participants. Neuroscience Applied, 3, 104060. https://doi.org/10.1016/j.nsa.2024.104060
Straumann, I., Vizeli, P., Avedisian, I., Erne, L., Noorshams, D., Vukalović, I., Eckert, A., Luethi, D., Rudin, D., & Liechti, M. E. (2025). Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants. Neuropsychopharmacology. https://doi.org/10.1038/s41386-025-02248-3
Strauss, D., Ghosh, S., Murray, Z., & Gryzenhout, M. (2022). An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus. Frontiers in Forests and Global Change, 5. https://doi.org/10.3389/ffgc.2022.813998
Suliman, S., Heuvel, L. L. van den, Bröcker, E., & Seedat, S. (2025). Neurocognitive difficulties in trauma-exposed adults with metabolic syndrome: no influence of PTSD status or PTSD and metabolic syndrome comorbidity. Discover Mental Health, 5(1). https://doi.org/10.1007/s44192-025-00141-5
Swainson, J., Klassen, L. J., Brennan, S., Chokka, P., Katzman, M. A., Tanguay, R. L., & Khullar, A. (2022). Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. CNS Drugs, 36(3), 239. https://doi.org/10.1007/s40263-022-00897-2
Tedesco, S., Gajaram, G., Chida, S., Ahmad, A., Pentak, M., Kelada, M., Lewis, L., Krishnan, D., Tran, C., Soetan, O. T., Mukona, L. T., & Jolayemi, A. (2021). The Efficacy of MDMA (3,4-Methylenedioxymethamphetamine) for Post-traumatic Stress Disorder in Humans: A Systematic Review and Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.15070
Tedla, A., Asnakew, S., Legas, G., Munie, B. M., Tareke, M., & Beka, M. (2024). Post-traumatic stress disorder among military personnel admitted at the Northwest Command Level Three Military Hospital, Bahir Dar, Ethiopia, 2022: an institution-based cross-sectional study. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1410630
Topel, M., & Ciccone, D. (2025). Ketamine Assisted EMDR TherapyTM for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy. European Journal of Psychotraumatology, 16(1), 2572861. https://doi.org/10.1080/20008066.2025.2572861
Torres‐Berrío, A., & Nava-Mesa, M. O. (2018). The opioid system in stress-induced memory disorders: From basic mechanisms to clinical implications in post-traumatic stress disorder and Alzheimer’s disease [Review of The opioid system in stress-induced memory disorders: From basic mechanisms to clinical implications in post-traumatic stress disorder and Alzheimer’s disease]. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 88, 327. Elsevier BV. https://doi.org/10.1016/j.pnpbp.2018.08.011
Tran, K., & MacDougall, D. (2024). Ketamine for Adults With Substance Use Disorders. Canadian Journal of Health Technologies, 4(2). https://doi.org/10.51731/cjht.2024.845
Turkia, M. (2024). 5-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood—a retrospective case study. https://doi.org/10.31234/osf.io/bvk2f
Underwood, M. (2025). THE USE OF IBOGAINE IN THE TREATMENT OF SUBSTANCE USE DISORDERS: INTEGRATING PSYCHOACTIVE EXPERIENCES AS PART OF THE RECOVERY JOURNEY. https://repository.canterbury.ac.uk/item/9vzv2/the-use-of-ibogaine-in-the-treatment-of-substance-use-disorders-integrating-psychoactive-experience-as-part-of-the-recovery-journey
Uthaug, M. V., Lancelotta, R., Oorsouw, K. van, Kuypers, K. P. C., Mason, N. L., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., Páleníček, T., Riba, J., & Ramaekers, J. G. (2019). A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology, 236(9), 2653. https://doi.org/10.1007/s00213-019-05236-w
Van Der Kolk, B. A., Wang, J. B., Yehuda, R., Bedrosian, L., Coker, A. R., Harrison, C., Mithoefer, M., Yazar-Klosinki, B., Emerson, A., Doblin, R., & Moitra, E. (2024). Effects of MDMA-assisted therapy for PTSD on self-experience. PLOS ONE, 19(1). https://doi.org/10.1371/journal.pone.0295926
Varker, T., Watson, L., Gibson, K., Forbes, D., & O’Donnell, M. L. (2021). Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. Journal of Psychoactive Drugs, 53(1), 85. https://doi.org/10.1080/02791072.2020.1817639
Vliet, N. I. van, Stant, A. D., Huntjens, R. J. C., Dijk, M. K. van, & Jongh, A. de. (2024). Cost-effectiveness analysis of the treatment of posttraumatic stress disorder related to childhood abuse: comparison of phase-based treatment and direct trauma-focused treatment. Frontiers in Psychology, 15. https://doi.org/10.3389/fpsyg.2024.1310372
Vorobyeva, N. S., & Kozlova, A. A. (2022). Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders [Review of Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders]. Frontiers in Pharmacology, 13. Frontiers Media. https://doi.org/10.3389/fphar.2022.927984
Wahba, M., Hayes, C., Kletter, M., & McAllister‐Williams, R. H. (2024). Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant’s experience. BJPsych Open, 10(6). https://doi.org/10.1192/bjo.2024.768
Wang, Y., Liu, L., Wang, J., Li, J., Li, H., Wang, R., Wang, H., Wang, M., Liu, Q., Fan, Z., Zhang, Y., Zhang, X., Wang, D., Wang, S., Xue, R., Mao, J., Cai, M., Wei, P., Dong, H., … Zhao, G. (2025). Time‐Dependent Therapeutic Effect of S ‐Ketamine on PTSD Mediated by VTA‐OFC Dopaminergic Neurocircuit. Advanced Science. https://doi.org/10.1002/advs.202500805
Wild, J., Duffy, M., & Ehlers, A. (2023). Moving forward with the loss of a loved one: treating PTSD following traumatic bereavement with cognitive therapy. The Cognitive Behaviour Therapist, 16. https://doi.org/10.1017/s1754470x23000041
Wojtas, A. (2023). The possible place for psychedelics in pharmacotherapy of mental disorders [Review of The possible place for psychedelics in pharmacotherapy of mental disorders]. Pharmacological Reports, 75(6), 1313. Elsevier BV. https://doi.org/10.1007/s43440-023-00550-9
Wolfgang, A., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodríguez, C. I., & Nemeroff, C. B. (2025). MDMA and MDMA-Assisted Therapy [Review of MDMA and MDMA-Assisted Therapy]. American Journal of Psychiatry, 182(1), 79. American Psychiatric Association. https://doi.org/10.1176/appi.ajp.20230681
Yerubandi, A., Thomas, J. E., Bhuiya, N. M. M. A., Harrington, C., Villa Zapata, L., & Caballero, J. (2024). Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Network Open, 7(4). https://doi.org/10.1001/jamanetworkopen.2024.5960
Yockey, R. A. (2025). Reconsidering Ibogaine for the treatment of severe mental illness and substance use disorders. Journal of Medicine, Surgery, and Public Health, 7, 100213. https://doi.org/10.1016/j.glmedi.2025.100213
Zeifman, R. J., Kettner, H., Ross, S., Weiss, B., Mithoefer, M. C., Mithoefer, A. T., & Wagner, A. C. (2024). Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder. European Journal of Psychotraumatology, 15(1), 2297536. https://doi.org/10.1080/20008066.2023.2297536
Copyright (c) 2025 Michal Gorski, Adam Januszkiewicz, Wiktoria Januszkiewicz, Wojciech Machulski, Martyna Ciarkowska, Jan Makulski, Kamil Franczyk, Karolina Swierk, Damian Podkoscielny, Maria Gierasimiuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
